US 12,303,527 B2
High molecular weight hyaluronic acid for treatment and prevention of severe ocular surface disease
Wolfgang Georg Konrad Müller-Lierheim, Munich (DE); and Gysbert-Botho Van Setten, Danderyd (SE)
Assigned to I.COM MEDICAL GMBH, Munich (DE)
Appl. No. 17/048,451
Filed by I.COM MEDICAL GMBH, Munich (DE)
PCT Filed Apr. 17, 2019, PCT No. PCT/EP2019/059965
§ 371(c)(1), (2) Date Oct. 16, 2020,
PCT Pub. No. WO2019/202017, PCT Pub. Date Oct. 24, 2019.
Claims priority of provisional application 62/659,215, filed on Apr. 18, 2018.
Prior Publication US 2021/0077523 A1, Mar. 18, 2021
Int. Cl. A61K 31/728 (2006.01); A61K 9/00 (2006.01); A61P 27/04 (2006.01)
CPC A61K 31/728 (2013.01) [A61K 9/0048 (2013.01); A61P 27/04 (2018.01)] 11 Claims
 
1. A method of treating severe ocular surface disease comprising:
a) measuring the ocular surface disease index (OSDI) of a human subject or a non-human subject and selecting a human subject or non-human animal subject having severe ocular surface disease, on the basis of an OSDI score of at least 33, for treatment with a fluid;
b) topically administering the fluid, said fluid comprising high molecular weight hyaluronic acid (HMWHA) to the ocular surface of the eye of the selected human subject or non-human animal subject having severe ocular surface disease, wherein the hyaluronic acid has an intrinsic viscosity of >2.5 m3/kg and a concentration of <0.2% w/v to reduce severe dry eye symptoms and wherein the severe ocular surface disease is: a) severe dry eye; b) caused by an external stimulus resulting in a disruption of the smoothness and/or integrity of the ocular surface;
or c) caused by an internal stimulus.